Shaikhoo

Is Orchid Pharma Turnaround Candidate?

BSE:ORCHIDPHAR   None
Shaikhoology's Stock Analysis
#OrchidPhar - 474

Overview:-
Business got into trouble and filed insolvency which was taken over by Dhanuka Laboratories in 2020

MOAT- Company have few patented products (API)

Topline:-
YOY & QOQ improvement seen in recent results.

Profit Growth is Organic and Margin Expansion clearly visible

BottomLine :-
Debt reduction, Good Reserves and Positive Cash Flow shows Financial stability.


Valuations:-
Overvalued as of Now.
If Earning Growth Continues then valuations can be cheaper, needs EPS of 10-15 then stock price will attract new investors.


Technically - Chart is bullish at Cmp and their is hurdles also as trading in WDZ

Stock May See 1000-1200 levels(WSZ) if trades and sustains above 550 levels.

SHARED FOR EDUCATIONAL PURPOSE ONLY, I AM NOT SEBI REGISTERED ANALYST.
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.